Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-03-25
- Target Recruit Count
- 320
- Registration Number
- NCT06327932
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 148
- Registration Number
- NCT06323239
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 540
- Registration Number
- NCT06319820
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇦🇹Medizinische Universitaet Graz, Graz, Austria
🇧🇷Associacao Hospitalar Moinhos de Vento, Porto Alegre, Brazil
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06313970
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 780
- Registration Number
- NCT06312137
- Locations
- 🇨🇳
Zhongshan Hospital of Fudan University ( Site 1325), Shangai, Shanghai, China
🇫🇷Groupe hospitalier Paris saint Joseph. ( Site 1807), Paris, Ile-de-France, France
🇫🇷Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1810), Clermont-Ferrand, Puy-de-Dome, France
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT06308419
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 286
- Registration Number
- NCT06282575
- Locations
- 🇺🇸
The University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
🇺🇸Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
🇺🇸Laura and Isaac Perlmutter Cancer Center at NYU Langone - Ambulatory Care Center, New York, New York, United States
A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06278493
- Locations
- 🇨🇳
Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 302
- Registration Number
- NCT06268652
- Locations
- 🇨🇳
Yanxia Shi, Guangzhou, None Selected, China
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06261359
- Locations
- 🇨🇳
Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.